Kamada receives Canadian patent

David Tsur  photo: Tamar Matzapi

Kamada CEO David Tsur: This patent will support future penetration into the Canadian market with our AAT therapy.

Kamada Ltd. (TASE: KMDA) has received an allowance from the Canadian Intellectual Property Office (CIPO) for Patent Application No. 2,538,998 entitled, “Large Scale Preparation of Alpha-1 Proteinase Inhibitor and Use Thereof.”

The allowed patent covers a large scale manufacturing process for production of Alpha-1 Proteinase Inhibitor, which significantly improves its production capacity.

“This patent will support future penetration into the Canadian market with our AAT therapy, where there are estimated to be many alpha-1 antitrypsin deficiency (AATD) patients, the majority of whom are not treated,” said Kamada co-founder and CEO David Tsur.

“Securing global protection for our novel plasma-derived products production technologies, including methods of use and manufacturing processes, is critically important as we develop highly-purified AAT in both intravenous and inhaled methods of administration to address major unmet needs in a variety of important disease states including pulmonary diseases, type-1 diabetes and Graft-versus-Host disease, to name a few. “Baxter Healthcare Corporation was granted distribution rights in Canada for our intravenous AAT product, Glassia, but has not commenced selling in this territory to date. In addition, two of the sites from the Phase 2/3 clinical trial of our inhaled AAT therapeutic to treat AATD were conducted in Canada, one of which was at the clinic of Kenneth R. Chapman, MD, Director, Asthma & Airway Centre, University Health Network, Professor of Medicine, University of Toronto, who is also part of our EU inhaled AAT trial advisory group. “As the leaders in the clinical development of AAT for multiple therapeutic indications, we continue to strengthen our global patent portfolio to support and protect our current products and technologies and to provide leverage in potentially monetizing these assets worldwide,” Tsur added.

Kamada's share price on the Tel Aviv Stock Exchange is currently up 1.04%, at NIS 18.48.

Published by Globes [online], Israel business news - www.globes-online.com - on April 2, 2015

© Copyright of Globes Publisher Itonut (1983) Ltd. 2015

David Tsur  photo: Tamar Matzapi
David Tsur photo: Tamar Matzapi
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018